RecruitingNCT03020381

Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study

Gait as Predictor of Cognitive Decline, Dementia, and Risk of Falls in MCI. A Cohort Study


Sponsor

Manuel Montero Odasso

Enrollment

600 participants

Start Date

Dec 1, 2007

Study Type

OBSERVATIONAL

Conditions

Summary

Motor slowing and cognitive slowing are more prevalent as we age. Importantly, the presence of both in an older person increases their risk of having dementia by ten times. Currently, there are no clinically meaningful predictors of progression to dementia in people with mild cognitive impairment (MCI). The main hypothesis is that subtle variations in gait while performing a simple cognitive task is a reliable, easy to perform, and feasible methodology to detect those older adults at higher risk of progression to dementia and also, at higher risk of further mobility decline and falls. Rationale. The Canadian population is aging. According to recent estimates, the proportion of the population aged 65 and older will increase rapidly from 13% in 2005 to 25% by 2031. This increase in proportion is accompanied by a considerable amount of disability and subsequent dependency which has major effects on both the quality of life of older adults and their caregivers, and on the Canadian health care system. An important goal of geriatric medicine is to reduce the gap between life expectancy and disability-free life expectancy by reducing disability and dependency in the later years of life. A substantial portion of this disability stems from two major geriatric syndromes: cognitive impairment and mobility limitation. The ultimate manifestations of these syndromes are dementia and falls. Interestingly, these manifestations often coexist in elderly people: falling is a common geriatric syndrome affecting about a third of older adults each year, and dementia affects about a third of Canadians aged 80 and over. Together, dementia and falls are responsible for much of the discomfort, disability, and health care utilization in older adults and each will become more prevalent as older Canadians are expected to number approximately $9 million by 2031. The combined direct cost of dementia and falls for the Canadian Health System is over $4.9 billion per year. Establishing reliable and easy to obtain predictors to accurately identify MCI patients at highest risk of progressing to dementia is essential first, to determine who will benefit from additional and/or invasive testing and second, to implement preventative strategies, including cognitive training, physical exercises, and aggressive vascular risk factors correction to delay progression. Even a modest one-year delay in dementia incidence could save Canada $109 billion over 30 years.


Eligibility

Min Age: 60 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This long-term study investigates whether the way a person walks can predict whether they will develop dementia or experience falls as they age, helping researchers identify early warning signs before symptoms appear. **You may be eligible if...** - You are between 60 and 85 years old - You do not have dementia - You can walk 10 meters (about 33 feet) on your own without a walking aid (such as a cane or walker) **You may NOT be eligible if...** - You do not speak English - You have Parkinson's disease or a neurological condition that affects how you move (such as a prior stroke or epilepsy with lasting motor effects) - You have a muscle or joint condition that significantly affects your walking - You have active arthritis in your legs or hips - You take medications that can affect movement (such as certain antipsychotics or sedatives) - You have severe depression Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Gait and Brain Lab, Parkwood Institute

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03020381


Related Trials